Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Abstract

We used 18F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec). The pilot study included nine patients with progressive AF receiving oral treatment with imatinib at a daily dose of 800 mg. Patients were examined using PET prior to the… (More)
DOI: 10.1007/s00259-010-1498-x

Topics

4 Figures and Tables

Cite this paper

@article{Kasper2010PositronET, title={Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib}, author={Bernd Kasper and Antonia Dimitrakopoulou-Strauss and Ludwig G. Strauss and Peter Hohenberger}, journal={European Journal of Nuclear Medicine and Molecular Imaging}, year={2010}, volume={37}, pages={1876-1882} }